Nxera Pharma Achieves Second Development Milestone in Eli Lilly Collaboration

The milestone payment validates Nxera's GPCR drug discovery platform and advances their partnership targeting metabolic diseases.

Apr. 9, 2026 at 1:03am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a group of polished, geometric pharmaceutical vials and bottles in shades of blue, gray, and white, arranged elegantly on a clean, monochromatic seamless background with dramatic lighting and shadows.Nxera's innovative drug discovery platform continues to yield promising results through its collaboration with Eli Lilly, advancing new treatments for metabolic diseases.Cambridge Today

Nxera Pharma, a Japanese biopharmaceutical company, has achieved a second development milestone in its multi-target collaboration with Eli Lilly, resulting in an undisclosed payment. The milestone represents significant progress in the companies' joint efforts to leverage Nxera's GPCR-focused drug discovery platform to develop new treatments for diabetes and other metabolic diseases.

Why it matters

This milestone demonstrates the success of Nxera's innovative GPCR-based drug discovery approach and validates its potential to yield promising therapeutic candidates. The collaboration with Lilly, a leading global pharmaceutical company, also highlights Nxera's growing reputation and ability to attract high-profile partnerships as it works to expand its pipeline and bring new medicines to market.

The details

Under the 2022 multi-target collaboration agreement, Nxera and Lilly are leveraging Nxera's NxWave™ platform to identify small molecule binders to GPCR targets and solve the receptor structure, revealing the binding site. This latest milestone payment indicates that Nxera has successfully achieved another key development goal, with Lilly now responsible for further advancement and commercialization. In total, Nxera is eligible for up to $694 million in development and commercial milestones, plus tiered royalties on global sales.

  • Nxera and Lilly entered the multi-target collaboration in 2022.
  • Nxera announced the achievement of the second development milestone on April 9, 2026.

The players

Nxera Pharma Co., Ltd.

A Japanese biopharmaceutical company focused on developing innovative medicines, including several launched products, to address unmet needs in Japan and globally. Nxera operates at key locations in Asia, Europe, and the UK, and is listed on the Tokyo Stock Exchange.

Eli Lilly and Company

A leading global pharmaceutical company with extensive expertise in drug development, commercialization, and therapeutic areas such as diabetes and metabolic diseases.

Got photos? Submit your photos here. ›

What they’re saying

“The achievement of this development milestone validates the use of Nxera's NxWave™ platform to successfully identify small molecule binders to GPCR targets and to solve the structure of the receptor in the presence of the small molecule, thus revealing its binding site.”

— Shinya Tsuzuki, VP, Head of Investor Relations

What’s next

Lilly will now be responsible for further development and commercialization of the compounds resulting from the collaboration with Nxera.

The takeaway

This milestone reinforces Nxera's position as an innovative biopharmaceutical company with a promising GPCR-focused drug discovery platform. The continued success of the Lilly collaboration underscores Nxera's ability to attract high-profile partnerships and advance its pipeline of potential new treatments for metabolic diseases.